To perform solid-phase assays, recipient serum is incubated with purified HLA antigens presented on a solid-phase platform (commonly microparticle beads). A fluorescent-conjugated anti-human IgG is added, which binds to and detects HLA antibody on its antigen target when the beads are analyzed on a flow cytometer or Luminex platform. The latter platform generates a semiquantitative output for each bead of mean fluorescence intensity, which is compared with negative control mean fluorescence intensity to determine if HLA antibody is present, It has proven difficult to align mean fluorescence intensity measurements within and between laboratories notwithstanding the increased reporting of this metric in published research.
No comments:
Post a Comment